References
- Borbás T, Benko B, Dalmadi B, Szabó I, Tihanyi K. (2006). Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Eur J Pharm Sci 28:51–8.
- Champney WS, Tober CL. (1998). Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol 37:418–25.
- Chiou WL. (1978). Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539–46.
- Choi YH. (2008). Dose-independency, first-pass effects, pharmacokinetics in various disease models, and drug interaction with DA-8159 or nifedipine of metformin in rats. PhD thesis, Seoul National University, Seoul.
- Choi YH, Chung SJ, Lee MG. (2008a). Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2. Br J Pharmacol 153:1568–78.
- Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543–52.
- Choi YH, Lee MG. (2006). Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1, and 3A1/2 for the metabolism of metformin. Br J Pharmacol 149:424–30.
- Choi YH, Lee DC, Lee I, Lee MG. (2008b). Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci 97:5363–75.
- Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61–90.
- Edelstein PH, Edelstein MA. (1999). In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 43:90–5.
- Falguera M, Martin M, Ruiz-Gonzalez A, Pifarre R, Garcia M. (2005). Community-acquired pneumonia as the initial manifestation of serious underlying diseases. Am J Med 118:378–83.
- Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York, NY: Marcel-Dekker.
- Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. (2002). Transfer of metformin into human milk. Diabetologia 45:1509–14.
- Hatanaka Y, Zamami Y, Koyama T, Hobara N, Jin X, Kitamura Y. (2008). A ketolide antibiotic, telithromycin, inhibits vascular adrenergic neurotransmission in the rat mesenteric vascular bed. Br J Pharmacol 155:826–36.
- Kim SH, Choi YM, Lee MG. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1–17.
- Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114–23.
- Lee JH, Lee MG. (2007a). Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: negligible effects of increase in CYP3A1 on the metabolism of telithromycin. Biopharm Drug Dispos 28:157–66.
- Lee JH, Lee MG. (2007b). Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability. J Pharm Pharm Sci 10:37–50.
- Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915–24.
- Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623–40.
- Nosaka H, Nadai M, Kato M, Yasui K, Yoshizumi H, Miyoshi M. (2006). Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats. Life Sci 79:50–6.
- Scheen AJ. (1996). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359–71.
- Shakeri-Nejad K, Stahlmann R. (2006). Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 7:639–51.
- Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda, K. (1993). Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 46:621–7.